LIMN vs IVF

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

LIMN

62.2
AI Score
VS
LIMN Wins

IVF

32.2
AI Score

Investment Advisor Scores

LIMN

62score
Recommendation
STRONG BUY

IVF

32score
Recommendation
EXTENDED

AI Analyst Insights

Detailed Metrics Comparison

Metric LIMN IVF Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 0.0% 16.7% IVF
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 62.2/100 32.2/100 LIMN
Profit Margin 0.0% -92.3% LIMN
Beta 1.00 1.00 Tie
AI Recommendation STRONG BUY EXTENDED LIMN

Relative Price Performance (Last 90 Days)

LIMN 1M: -19.7% · 3M: +2453.0% IVF 1M: +244.4% · 3M: +147.5%

Current Technical Phase

LIMN

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 43

RSI (14): 43.4 · Price: $2.77

IVF

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.8% over 20 days), RSI 87

RSI (14): 86.5 · Price: $2.50

Fundamentals Snapshot

Metric LIMN IVF
Market Cap — —
Forward P/E 0.0 -0.1
Trailing P/E — 0.0
Revenue (TTM) — —
Revenue Growth 0.0% 0.2%
Gross Margin — 0.4%
Operating Margin 0.0% -0.6%
EPS -23.50 511.80
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, LIMN is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.